Trial Profile
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROFILE-1014
- Sponsors Pfizer
- 26 Feb 2019 Results of pooled analysis (data cutoff date 15 July 2014) of four clinical trials (NCT00585195,NCT00932451,NCT00932893 and NCT01154140) evaluating renal effects of crizotinib in patients with advanced Non-Small Cell Lung Cancer published in the Journal of Thoracic Oncology
- 13 Jul 2018 Results assessing Crizotinib efficacy in three prospective studies ((PROFILE 1005, PROFILE 1007, and PROFILE 1014), were published in the Annals of Oncology.
- 16 May 2018 Results of final overall survival a key secondary endpoint data published in the Journal of Clinical Oncology.